{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:18:40Z","timestamp":1792513120714,"version":"4.5.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetic kidney disease (DKD) affects 30\u201340% of all patients with diabetes and contributes significantly to the cardiovascular burden of chronic kidney disease (CKD). Despite the availability of evidence-based medications like finerenone and simple screening tests such as Urinary Albumin-to-Creatinine Ratio (UACR), more resources are still needed to care for DKD patients. Physician Associates (PAs) play a crucial role in the multidisciplinary team responsible for DKD diagnosis, monitoring, and management. A nonsteroidal mineralocorticoid receptor antagonist, namely finerenone, was approved by the FDA in adults with CKD associated with type 2 diabetes to reduce the risk of renal and cardiovascular outcomes. Finerenone is considered among the pillars of care for DKD, furthermore, the addition of finerenone in combination with renin-angiotensin system inhibitors and\/or other renal protective medications may offer additional benefits. Primary care providers prescribe finerenone less frequently than specialized care providers, indicating a need to empower physician associates in medication prescription and other renal protection strategies. As part of a multidisciplinary team, physician associates can play an important role in evaluating risk factors that contribute to heart disease and metabolic health. They can also monitor not only kidney function by ordering tests, such as serum creatinine and urinary albumin-to-creatinine ratio every 3\u201312\u00a0months, but also serum potassium levels. Additionally, physician associates can encourage patients to take responsibility for their health by regularly monitoring their blood pressure, blood glucose levels, and body weight. With early detection and management, kidney failure and cardiovascular events may be preventable. Specialized physician associates also play a significant role in the comprehensive care of DKD patients, especially in the later stages. DKD care can be hindered by numerous factors such as lack of patient engagement during counseling, cost disparities, and a complex referral system that requires multidisciplinary guidelines to improve professional communication. It is necessary to re-envision the physician associates\u2019 role in primary care and empower them in goal-directed therapies.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s40620-024-02015-5","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T01:03:35Z","timestamp":1719968615000},"page":"2161-2170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Finerenone: Who should prescribe it for CKD? The physician associate\u2019s perspective"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8483-439X","authenticated-orcid":false,"given":"Becky M.","family":"Ness","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"issue":"1","key":"2015_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Supplements 12(1):7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003","journal-title":"Kidney Int Supplements"},{"key":"2015_CR2","unstructured":"CDC (2023) Chronic Kidney Disease in the United States 2023(22 July)"},{"issue":"1","key":"2015_CR3","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S et al (2015) Diabetic kidney disease. Nat Rev Dis Primers 1(1):15018. https:\/\/doi.org\/10.1038\/nrdp.2015.18","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2015_CR4","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1097\/TP.0000000000003360","volume":"104","author":"AS Levey","year":"2020","unstructured":"Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Cheung M, Jadoul M et al (2020) Nomenclature for kidney function and disease: executive summary and glossary from a kidney disease: improving global outcomes consensus conference. Transplantation 104(10):1986\u20131994. https:\/\/doi.org\/10.1097\/TP.0000000000003360","journal-title":"Transplantation"},{"issue":"2","key":"2015_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","volume":"79","author":"C Delgado","year":"2022","unstructured":"Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA et al (2022) A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis 79(2):268\u2013288. https:\/\/doi.org\/10.1053\/j.ajkd.2021.08.003. (e1)","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"2015_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825\u2013830. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00007","journal-title":"Ann Intern Med"},{"key":"2015_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100552","volume":"27","author":"K Matsushita","year":"2020","unstructured":"Matsushita K, Jassal SK, Sang Y, Ballew SH, Grams ME, Surapaneni A et al (2020) Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets. EClinicalMedicine 27:100552. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100552","journal-title":"EClinicalMedicine"},{"issue":"9854","key":"2015_CR8","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/s0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJL et al (2012) Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. The Lancet 380(9854):1662\u20131673. https:\/\/doi.org\/10.1016\/s0140-6736(12)61350-6","journal-title":"The Lancet"},{"issue":"12","key":"2015_CR9","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45(12):3075\u20133090. https:\/\/doi.org\/10.2337\/dci22-0027","journal-title":"Diabetes Care"},{"issue":"20","key":"2015_CR10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/nejm199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New Engl J Med 329(20):1456\u20131462. https:\/\/doi.org\/10.1056\/nejm199311113292004","journal-title":"New Engl J Med"},{"key":"2015_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110592","volume":"198","author":"Q Yang","year":"2023","unstructured":"Yang Q, Lang Y, Yang W, Yang F, Yang J, Wu Y et al (2023) Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 198:110592. https:\/\/doi.org\/10.1016\/j.diabres.2023.110592","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"2015_CR12","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","volume":"46","author":"SC Naaman","year":"2023","unstructured":"Naaman SC, Bakris GL (2023) Diabetic nephropathy: update on pillars of therapy slowing progression. Diabetes Care 46(9):1574\u20131586. https:\/\/doi.org\/10.2337\/dci23-0030","journal-title":"Diabetes Care"},{"issue":"6","key":"2015_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474\u2013484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"issue":"4","key":"2015_CR14","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK et al (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"1","key":"2015_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/wvn.12483","volume":"18","author":"HT Hsu","year":"2021","unstructured":"Hsu HT, Chiang YC, Lai YH, Lin LY, Hsieh HF, Chen JL (2021) Effectiveness of multidisciplinary care for chronic kidney disease: a systematic review. Worldviews Evid-Based Nurs 18(1):33\u201341. https:\/\/doi.org\/10.1111\/wvn.12483","journal-title":"Worldviews Evid-Based Nurs"},{"issue":"3","key":"2015_CR16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/ndt\/gfac283","volume":"38","author":"R Nee","year":"2023","unstructured":"Nee R, Yuan CM, Narva AS, Yan G, Norris KC (2023) Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant 38(3):532\u2013541. https:\/\/doi.org\/10.1093\/ndt\/gfac283","journal-title":"Nephrol Dial Transplant"},{"issue":"23","key":"2015_CR17","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"New Engl J Med"},{"issue":"24","key":"2015_CR18","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. New Engl J Med 385(24):2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"New Engl J Med"},{"issue":"15","key":"2015_CR19","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","volume":"81","author":"JE Frampton","year":"2021","unstructured":"Frampton JE (2021) Finerenone: first approval. Drugs 81(15):1787\u20131794. https:\/\/doi.org\/10.1007\/s40265-021-01599-7","journal-title":"Drugs"},{"key":"2015_CR20","unstructured":"Kerendia [package insert]. Bayer HealthCare Pharmaceuticals Inc; 2022."},{"key":"2015_CR21","unstructured":"NICE: Finerenone for treating chronic kidney disease in people with type 2 diabetes. https:\/\/www.nice.org.uk\/guidance\/TA877\/chapter\/1-Recommendations (2023). Accessed 18 September 2023."},{"issue":"12","key":"2015_CR22","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.3390\/jcm12123992","volume":"12","author":"L Di Lullo","year":"2023","unstructured":"Di Lullo L, Lavalle C, Scatena A, Mariani MV, Ronco C, Bellasi A (2023) Finerenone: questions and answers\u2014the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist. J Clin Med 12(12):3992. https:\/\/doi.org\/10.3390\/jcm12123992","journal-title":"J Clin Med"},{"issue":"12","key":"2015_CR23","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 45(12):2991\u20132998. https:\/\/doi.org\/10.2337\/dc22-0294","journal-title":"Diabetes Care"},{"issue":"1","key":"2015_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.14558","volume":"24","author":"P Rossing","year":"2022","unstructured":"Rossing P, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM et al (2022) Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab 24(1):125\u2013134. https:\/\/doi.org\/10.1111\/dom.14558","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2015_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"issue":"15","key":"2015_CR26","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"issue":"24","key":"2015_CR27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/nejmoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/nejmoa1811744","journal-title":"New Engl J Med"},{"issue":"4","key":"2015_CR28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","volume":"38","author":"JB Green","year":"2023","unstructured":"Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB et al (2023) Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant 38(4):894\u2013903. https:\/\/doi.org\/10.1093\/ndt\/gfac198","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2015_CR29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"IH De Boer","year":"2020","unstructured":"De Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K et al (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98(4):S1\u2013S115. https:\/\/doi.org\/10.1016\/j.kint.2020.06.019","journal-title":"Kidney Int"},{"key":"2015_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.03.021","author":"S Jimenez-Marrero","year":"2024","unstructured":"Jimenez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Enjuanes C, Yun S et al (2024) Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: a population-based analysis. Eur J Intern Med. https:\/\/doi.org\/10.1016\/j.ejim.2024.03.021","journal-title":"Eur J Intern Med"},{"issue":"Suppl 3","key":"2015_CR31","doi-asserted-by":"publisher","first-page":"iii51","DOI":"10.1093\/ndt\/gfz213","volume":"34","author":"S Bianchi","year":"2019","unstructured":"Bianchi S, Regolisti G (2019) Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. Nephrol Dial Transplant 34(Suppl 3):iii51\u2013iii61. https:\/\/doi.org\/10.1093\/ndt\/gfz213","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2015_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/ndt\/gfac041","volume":"38","author":"T Imasawa","year":"2023","unstructured":"Imasawa T, Saito C, Kai H, Iseki K, Kazama JJ, Shibagaki Y et al (2023) Long-term effectiveness of a primary care practice facilitation program for chronic kidney disease management: an extended follow-up of a cluster-randomized FROM-J study. Nephrol Dial Transplant 38(1):158\u2013166. https:\/\/doi.org\/10.1093\/ndt\/gfac041","journal-title":"Nephrol Dial Transplant"},{"key":"2015_CR33","unstructured":"AAMC: The complexities of physician supply and demand: projections from 2019 to 2034. https:\/\/www.aamc.org\/news\/press-releases\/aamc-report-reinforces-mounting-physician-shortage (2021). Accessed September 20 2023."},{"key":"2015_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-017-0701-6","author":"B Leach","year":"2017","unstructured":"Leach B, Morgan P, Strand De Oliveira J, Hull S, \u00d8stbye T, Everett C (2017) Primary care multidisciplinary teams in practice: a qualitative study. BMC Family Pract. https:\/\/doi.org\/10.1186\/s12875-017-0701-6","journal-title":"BMC Family Pract"},{"key":"2015_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad073","author":"RM Zhang","year":"2023","unstructured":"Zhang RM (2023) Single institution prescribing pattern of finerenone in patients with type 2 diabetes and\/or chronic kidney disease in the USA. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfad073","journal-title":"Clin Kidney J"},{"issue":"11","key":"2015_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/01.JAA.0000502863.13352.bf","volume":"29","author":"K Thomsen","year":"2016","unstructured":"Thomsen K, Zuber K, Davis J, Thomas G (2016) Improving treatment for patients with chronic kidney disease. JAAPA 29(11):46\u201353","journal-title":"JAAPA"},{"issue":"5","key":"2015_CR37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","author":"National Kidney F","year":"2012","unstructured":"National Kidney F (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850\u2013886. https:\/\/doi.org\/10.1053\/j.ajkd.2012.07.005","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2015_CR38","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K et al (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102(5):S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"2015_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxad192","author":"E Ashjian","year":"2023","unstructured":"Ashjian E, Clarke M, Pogue K (2023) Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes. Am J Health-Syst Pharmacy. https:\/\/doi.org\/10.1093\/ajhp\/zxad192","journal-title":"Am J Health-Syst Pharmacy"},{"key":"2015_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02367-1","author":"C Van Dipten","year":"2021","unstructured":"Van Dipten C, Van Dam DGHA, De Grauw WJC, Ten Dam MAGJ, Hermans MMH, Assendelft WJJ et al (2021) Referring patients with chronic kidney disease back to primary care: a criteria-based analysis in outpatient renal clinics. BMC Nephrol. https:\/\/doi.org\/10.1186\/s12882-021-02367-1","journal-title":"BMC Nephrol"},{"issue":"1","key":"2015_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.JAA.0000723944.52480.d8","volume":"34","author":"J Davis","year":"2021","unstructured":"Davis J, Zuber K (2021) The changing landscape of PAs and NPs in nephrology. JAAPA 34(1):1\u20138","journal-title":"JAAPA"},{"issue":"7","key":"2015_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.JAA.0000466586.10595.2e","volume":"28","author":"DK Link","year":"2015","unstructured":"Link DK (2015) Chronic kidney disease: new paradigms in diagnosis and management. JAAPA 28(7):23\u201328. https:\/\/doi.org\/10.1097\/01.JAA.0000466586.10595.2e","journal-title":"JAAPA"},{"key":"2015_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.754239","volume":"12","author":"D Kawanami","year":"2021","unstructured":"Kawanami D, Takashi Y, Muta Y, Oda N, Nagata D, Takahashi H et al (2021) Mineralocorticoid receptor antagonists in diabetic kidney disease. Front Pharmacol 12:754239. https:\/\/doi.org\/10.3389\/fphar.2021.754239","journal-title":"Front Pharmacol"},{"issue":"5","key":"2015_CR44","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1365-2753.2009.01235.x","volume":"16","author":"C Van Walraven","year":"2010","unstructured":"Van Walraven C, Oake N, Jennings A, Forster AJ (2010) The association between continuity of care and outcomes: a systematic and critical review. J Eval Clin Pract 16(5):947\u2013956. https:\/\/doi.org\/10.1111\/j.1365-2753.2009.01235.x","journal-title":"J Eval Clin Pract"},{"key":"2015_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0932-3","author":"YJ Jang","year":"2018","unstructured":"Jang YJ, Choy YS, Nam CM, Moon KT, Park E-C (2018) The effect of continuity of care on the incidence of end-stage renal disease in patients with newly detected type 2 diabetic nephropathy: a retrospective cohort study. BMC Nephrol. https:\/\/doi.org\/10.1186\/s12882-018-0932-3","journal-title":"BMC Nephrol"},{"issue":"10","key":"2015_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/01.JAA.0000545065.71225.f5","volume":"31","author":"K Zuber","year":"2018","unstructured":"Zuber K, Davis J (2018) The ABCs of chronic kidney disease. JAAPA 31(10):17\u201325","journal-title":"JAAPA"},{"issue":"4","key":"2015_CR47","first-page":"e107","volume":"24","author":"TD Sequist","year":"2018","unstructured":"Sequist TD, Holliday AM, Orav EJ, Bates DW, Denker BM (2018) Physician and patient tools to improve chronic kidney disease care. Am J Manag Care 24(4):e107\u2013e114","journal-title":"Am J Manag Care"},{"key":"2015_CR48","doi-asserted-by":"crossref","unstructured":"Dayer VW, Hansen RN, Singh R, Kong SX, Williamson T, Sullivan SD. Potential budget impact of finerenone in patients with chronic kidney disease and type 2 diabetes being treated with standard of care. Value in Health: ELSEVIER SCIENCE INC STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA; 2022. p. S413-S.","DOI":"10.1016\/j.jval.2022.04.645"},{"issue":"10","key":"2015_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20969","volume":"3","author":"J Luo","year":"2020","unstructured":"Luo J, Feldman R, Rothenberger SD, Hernandez I, Gellad WF (2020) Coverage, formulary restrictions, and out-of-pocket costs for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in the medicare Part D program. JAMA Netw Open 3(10):e2020969. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.20969","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2015_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1286\/jrip.2014.20","volume":"3","author":"CM Junaid Nazar","year":"2014","unstructured":"Junaid Nazar CM, Kindratt TB, Ahmad SM, Ahmed M, Anderson J (2014) Barriers to the successful practice of chronic kidney diseases at the primary health care level; a systematic review. J Renal Inj Prev 3(3):61\u201367. https:\/\/doi.org\/10.1286\/jrip.2014.20","journal-title":"J Renal Inj Prev"},{"issue":"12","key":"2015_CR51","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.37193","volume":"4","author":"K Ladin","year":"2021","unstructured":"Ladin K, Porteny T, Perugini JM, Gonzales KM, Aufort KE, Levine SK et al (2021) Perceptions of telehealth vs in-person visits among older adults with advanced kidney disease, care partners, and clinicians. JAMA Netw Open 4(12):e2137193. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.37193","journal-title":"JAMA Netw Open"},{"key":"2015_CR52","doi-asserted-by":"publisher","first-page":"205435812210812","DOI":"10.1177\/20543581221081207","volume":"9","author":"L Dubrofsky","year":"2022","unstructured":"Dubrofsky L, Lee JF, Hajimirzarahimshirazi P, Liu H, Weisman A, Lawler PR et al (2022) A unique multi- and interdisciplinary cardiology-renal-endocrine clinic: a description and assessment of outcomes Canadian. J Kidney Health Dis 9:205435812210812. https:\/\/doi.org\/10.1177\/20543581221081207","journal-title":"J Kidney Health Dis"},{"issue":"10","key":"2015_CR53","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","volume":"28","author":"L Blonde","year":"2022","unstructured":"Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M et al (2022) American Association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract 28(10):923\u20131049. https:\/\/doi.org\/10.1016\/j.eprac.2022.08.002","journal-title":"Endocr Pract"},{"key":"2015_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02015-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02015-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02015-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:39Z","timestamp":1777564419000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/8\/2161\/8306359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["2015"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02015-5","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors, Becky M. Ness and Heidi Webb, do not have any competing interests in relation to this review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for this review article was not applicable as it did not involve human participants and\/or human tissues.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent to participate was not applicable for this review article as it did not have any individual participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}}]}}